Lu, Roberts, Bartfai and colleagues at Scripps Research have now developed a compound that targets the galanin system, but unlike the previous agonist, is more selective in its action. The compound, called CYM2503, binds to one of three galanin receptors on nerve cells, the galanin receptor type 2 . In itself has no effect on CYM2503 GalR2, galanin but when it also binds to the receptor, enhances the function of galanin CYM2503.‘It ‘a double step forward,’ says Bartfai. ‘The first compound is a new mode of action of anticonvulsants and represents a new molecular mechanism of action.’
Because it works only when CYM2503 galanin, a natural molecule, is also present, the researchers predict that will have fewer side effects than drugs that work on their own. This study provides the first evidence that modulation of the GalR2 receptor is an effective strategy for treating seizures, opening the door to developing drugs that target this mechanism.
Recent research suggests that when crises occur in the brain intensifies the production of galanin, probably a way to protect against the crisis. As a result, mice engineered to lack galanin are more prone to developing crises.
A chemical compound that stimulates the action of a molecule normally produced in the brain can be the starting point for a new line of therapy for the treatment of epileptic seizures, according to new research by scientists at The Scripps Research Institute.
As described in the Proceedings of the National Academy of Sciences , the new compound effectively reduces the frequency and severity of seizures in mice and rats.
In addition to Lu, and Bartfai Roberts, co-authors of the paper include Fengcheng Xia, Manuel Sanchez-Alvarez, Tianyu Liu, Stephanie and James Chang Wu Scripps Research, and Roger G. Baldwin and Claude Wasterlain Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine, University of California at Los Angeles.
‘This made it really gives a new perspective for the development of drugs to treat seizures,’ says Scripps Research Assistant Professor Lu Xiaoying, who co-authored the paper with Professor Edward Roberts, President of Molecular and Integrative Neuroscience Tamas Bartfai department and colleagues.
However, as much as 30 % of people with epilepsy do not respond to current drugs, making the search for additional drugs that act by different mechanisms, even urgent.
‘Based on the known functions of the GalR2 receptor, may also work in the treatment of depression and protect the brain from damage,’ said Lu
Other tumor samples tested 439 Meeker, Papadopoulos and his colleagues, the ATRX mutations have been found in different types of brain cancer, including pediatric and adult glioblastoma samples provided by Hai Yan, MD, Ph.D., and Darell Bigner, MD, Ph.D., of Duke University
Approximately 50 million people worldwide suffer from epilepsy, a disease characterized by recurrent unprovoked seizures. Following these items, people can have violent muscle spasms or loss of consciousness and, in some cases, suffer brain damage or die. Dozen or more drugs on the market to treat epilepsy work aims to reduce this excessive cooking especially the mechanisms by which neurons send signals to another.
The researchers tested the effects of CYM2503 in mice and rats treated with a chemical that causes them to have seizures. Animals that have received CYM2503 required more time for the crisis, and when they did, the crisis lasted a shorter time.
In particular, when the researchers examined the animals after 24 hours, mice were treated with CYM2503 had a significantly higher survival rate than those without.